Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Compugen to Significantly Expand Immuno-Oncology Activities During 2014

Published: Wednesday, January 08, 2014
Last Updated: Tuesday, January 07, 2014
Bookmark and Share
R&D expenditures for 2014 anticipated to increase by more than 60%.

Compugen Ltd. has announced that it is significantly increasing its Pipeline Program activities in the field of immuno-oncology. The primary purpose of the increase is to allow research and preclinical activities for a larger number of checkpoint target and product candidates for cancer immunotherapy to move forward in parallel.

Additional objectives include the establishment of a biomarker discovery program for certain of the Company’s checkpoint product candidates and the acceleration of experimental validation efforts for the recently disclosed antibody drug conjugate (ADC) target candidates for oncology.

The significant increase in immuno-oncology activities during 2014 will impact both the target research and validation activities performed in Israel and the therapeutic antibody development efforts against Compugen-discovered drug targets undertaken by the Company's U.S. R&D subsidiary. This includes the scheduled relocation of the U.S. subsidiary to larger facilities in the South San Francisco area in mid-year.

Dr. Anat Cohen-Dayag, Compugen’s President and CEO, stated, “These expanded activities are anticipated to result in more than a sixty percent increase in our annual R&D cash expenditures, from approximately $10 million in 2013 to more than $16 million budgeted for 2014. Having begun 2014 with more than $50 million in available resources, we are confident that this increased R&D budget, providing for a substantially expanded program in oncology while maintaining approximately the same level of expenditures for the immunology arm of our Pipeline Program, is fully consistent with our financial status and outlook.”

Dr. Cohen-Dayag continued, “The field of immuno-oncology is now being described as providing a paradigm shift in cancer treatment. But despite the recent impressive clinical success of antibodies against immune checkpoint regulators, the majority of treated patients do not respond when treated with one drug, suggesting that additional checkpoints are driving immune suppression in non-responders. Therefore, an area of significant current focus in this field is to increase the percentage of responders through the use of drug combinations, including additional checkpoint inhibitors and other drugs. Accordingly, we believe, Compugen’s multiple novel checkpoint candidates offer timely and unique therapeutic and commercial opportunities.”

Dr. Cohen-Dayag explained, “Several years ago Compugen selected the field of immuno-oncology as its first focused discovery program, resulting in very successful immune checkpoint target discovery and validation efforts. We begin 2014 with multiple early-stage novel immune checkpoint candidates, in addition to the two that are the subject of a collaboration and license agreement signed last year. Moving forward, our increased oncology R&D budget is expected to allow us to advance more of these candidates in parallel, both for future additional early stage collaborations and our own internal development towards human clinical trials. Furthermore, since certain biomarkers, such as companion diagnostics, are expected to be highly beneficial in this rapidly growing field of immuno-oncology, we plan to establish a predictive biomarker discovery program for certain of our product candidates.”

Dr. Cohen-Dayag concluded, “During 2014 we look forward to further demonstrating, both scientifically and commercially, the value of the unique and powerful predictive discovery infrastructure that has been created by Compugen, which we continue to enhance. Similar to last year, we expect to include in our 2013 yearend press release and conference call selected corporate objectives established for the current year.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Discloses New Results Supporting CGEN-15052
Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City.
Thursday, September 17, 2015
Compugen Obtains Rights to Use Biological Systems and Materials
Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs.
Wednesday, April 15, 2015
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
New facilities double available space for corporate offices and research and discovery in Israel.
Wednesday, March 25, 2015
Compugen Expands and Strengthens Business Development Team
Felix Karim, PhD, joins Company as Vice President Corporate & Business Development.
Tuesday, March 10, 2015
Compugen Discloses Initial Experimental Results for Predicted ADC Targets
Pipeline program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs.
Tuesday, January 06, 2015
Compugen Announces Presentations of Results for CGEN-15001
Data indicating novel mechanism of action for CGEN-15001 in maintaining long-term therapeutic effect presented at International Conference on Immune Tolerance in Amsterdam.
Wednesday, October 01, 2014
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Reports Fourth Quarter and Calendar 2013 Results
Company discloses key 2014 corporate objectives.
Wednesday, February 12, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.
Thursday, December 12, 2013
Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model
Short-term administration of CGEN-15001 shown to provide long-term prevention of disease development.
Friday, October 11, 2013
Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types
CGEN-15049 immune checkpoint protein expressed on wide variety of cancers.
Thursday, September 26, 2013
Compugen Establishes SAB to Guide Pipeline Program Development
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.
Tuesday, August 27, 2013
Compugen Announces Collaboration and License Agreement with Bayer
Compugen to hold 2nd Quarter Conference Call August 7, 2013.
Tuesday, August 06, 2013
Compugen Reports First Quarter 2013 Financial Results
CEO to update Company status in quarterly conference call.
Monday, April 29, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
Kitchen Utensils Can Spread Bacteria Between Foods
In a recent study researchers found that produce that contained bacteria would contaminate other produce items through the continued use of knives or graters—the bacteria would latch on to the utensils commonly found in consumers' homes and spread to the next item.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Safer, Faster Way To Remove Pollutants From Water
Using nanoparticles filled with enzymes proves more effective than current methods.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos